organization · Reporting owner

Fosun International Ltd

Disclosed activity across 2 companies

Tapewire entity: 118397
SEC CIK: 0001447884

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Amneal Pharmaceuticals, Inc.AMRX · Entity 820	10% owner	August 06, 2019	August 08, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amneal Pharmaceuticals, Inc.

Report date August 06, 2019 · Filed August 08, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Indirectby Peak Reinsurance Company Limited	327,000	Reported balance After 2019-08-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-08-06 · Purchase · Acquired 327,000 · Balance 327,000 F1: Peak Reinsurance Company Limited is a subsidiary of the Reporting Person.
Class A Common StockSEC Table I · non-derivative	Indirectby Fosun Atlas Capital SICAV RAIF S.C.S.	1,642,300	Reported balance Holding disclosure · report date 2019-08-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,642,300 F2: Fosun Atlas Capital SICAV RAIF S.C.S. is a fund managed by a wholly-owned subsidiary of the Reporting Person.
Class A Common StockSEC Table I · non-derivative	Indirectby Ambient Impact (HK) Limited	16,438,356	Reported balance Holding disclosure · report date 2019-08-06 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 16,438,356 F3: Ambient Impact (HK) Limited is a wholly-owned subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Peak Reinsurance Company Limited is a subsidiary of the Reporting Person.

F2: Fosun Atlas Capital SICAV RAIF S.C.S. is a fund managed by a wholly-owned subsidiary of the Reporting Person.

F3: Ambient Impact (HK) Limited is a wholly-owned subsidiary of the Reporting Person.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ViewRay, Inc.

Report date November 19, 2021 · Filed November 23, 2021

Section 16 reporting ended · disclosed 2021-11-23. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 08, 2021 Filed Nov 10, 2021 11:08 UTC	ViewRay, Inc. VRAY · Entity 111118	SaleCommon Stock	4,000,000	$7.02	$28,080,000.00	Disclosure SEC source: 0001104659-21-136572 · tm2132368d1_4.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Strong Influence Limited Disclosed balance after: 11,108,222 F1 · shares: These shares were sold in a block trade. F2 · ownership.nature: Strong Influence Limited is an indirectly wholly-owned subsidiary of the Reporting Person. Read SEC document
June 08, 2021 Filed Jun 10, 2021 11:02 UTC	ViewRay, Inc. VRAY · Entity 111118	SaleCommon Stock	4,300,000	$5.97	$25,671,000.00	Disclosure SEC source: 0001104659-21-079091 · tm2119248-2_4seq1.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Strong Influence Limited Disclosed balance after: 15,108,222 F1 · shares: These shares were sold in a block trade. F2 · ownership.nature: Strong Influence Limited is an indirectly wholly-owned subsidiary of the Reporting Person. Read SEC document
December 06, 2019 Filed Dec 10, 2019 17:48 UTC	ViewRay, Inc. VRAY · Entity 111118	PurchaseCommon Stock	1,597,444	$3.13	$4,999,999.72	Disclosure SEC source: 0001104659-19-071330 · tm1924774d1_4.xml · nonDerivative · entry 2 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Fosun Atlas Capital SICAV RAIF S.C.S. Disclosed balance after: 1,597,444 F1 · shares: These shares were acquired in a public offering by the Issuer. F3 · ownership.nature: Fosun Atlas Capital SICAV RAIF S.C.S. is a fund managed by an indirectly wholly-owned subsidiary of the Reporting Person. Read SEC document
December 06, 2019 Filed Dec 10, 2019 17:48 UTC	ViewRay, Inc. VRAY · Entity 111118	PurchaseCommon Stock	5,750,798	$3.13	$17,999,997.74	Disclosure SEC source: 0001104659-19-071330 · tm1924774d1_4.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Strong Influence Limited Disclosed balance after: 19,408,222 F1 · shares: These shares were acquired in a public offering by the Issuer. F2 · ownership.nature: Strong Influence Limited is an indirectly wholly-owned subsidiary of the Reporting Person. Read SEC document
August 06, 2019 Filed Aug 8, 2019 10:15 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	PurchaseClass A Common Stock	327,000	$2.91	$951,570.00	Disclosure SEC source: 0001144204-19-038365 · tv526990_form4.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Peak Reinsurance Company Limited Disclosed balance after: 327,000 F1 · ownership.nature: Peak Reinsurance Company Limited is a subsidiary of the Reporting Person. Read SEC document
August 05, 2019 Filed Aug 7, 2019 12:58 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	PurchaseClass A Common Stock	1,642,300	$3.04	$4,992,592.00	Disclosure SEC source: 0001144204-19-038060 · tv526865_form4.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Fosun Atlas Capital SICAV RAIF S.C.S. Disclosed balance after: 1,642,300 F1 · ownership.nature: Fosun Atlas Capital SICAV RAIF S.C.S. is a fund managed by a wholly-owned subsidiary of the Reporting Person. Read SEC document
August 30, 2018 Filed Aug 31, 2018 19:02 UTC	ViewRay, Inc. VRAY · Entity 111118	PurchaseCommon Stock	2,702,702	$9.25	$24,999,993.50	Disclosure SEC source: 0001144204-18-047548 · tv502171_form4.xml · nonDerivative · entry 1 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813,834 Read SEC document
May 21, 2018 Filed Aug 31, 2018 19:02 UTC	ViewRay, Inc. VRAY · Entity 111118	ConversionCommon Stock	3,000,581	$8.31	$24,934,828.11	Disclosure SEC source: 0001144204-18-047548 · tv502171_form4.xml · nonDerivative · entry 2 Fosun International Ltd · CIK 0001447884 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Strong Influence Limited Disclosed balance after: 3,000,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Strong Influence converted 3,000,581 shares of the Series A Convertible Preferred Stock into common stock on a one-for-one basis on May 21, 2018. F1 · ownership.nature: Strong Influence Limited ("Strong Influence") is an indirectly wholly-owned subsidiary of the Reporting Person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.